ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

THE GENETIC REVOLUTION: How CRISPR and Gene Editing Are Reshaping Medicine, Ethics, and Our Future

Dr Saloni Jain, Assistant Teacher, Samarkand State Medical University, Uzbekistan

15saloni2626@gmail.com

Jawed Akhtar, Medical Student, Samarkand State Medical University, Uzbekistan

jawedmedic@gmail.com

Ramdev Siyag, Medical Student, Samarkand State Medical University, Uzbekistan

rcjat7145@gmail.com

Mohd Danis, Medical Student, Samarkand State Medical University, Uzbekistan

mohddanis805@gmail.com

Mohd Anas, Medical Student, Samarkand State Medical University, Uzbekistan

Infoanaskhan01@gmail.com

Abstract

Gene editing represents one of the most transformative biotechnologies of the 21st century, offering unprecedented precision in modifying DNA to treat genetic diseases, enhance agricultural productivity, and potentially alter the trajectory of human evolution. This narrative article explores the revolutionary CRISPR-Cas9 technology, its clinical applications including the landmark FDA approval of Casgevy for sickle cell disease, emerging ethical frameworks, and the regulatory landscape shaping this rapidly evolving field. With the global gene editing market projected to reach $45 billion by 2035 , understanding this technology's capabilities, limitations, and societal implications has never been more critical.

Keywords: CRISPR-Cas9, Gene Editing, Casgevy, Sickle Cell Disease, Base Editing, Personalized Medicine, Bioethics, FDA Approval, Genetic Therapy, Off-Target Effects, Germline Editing, Therapeutic Genome Editing

The Discovery That Changed Everything

In 2012, a bacterial immune system became the most powerful tool in molecular biology. Jennifer Doudna and Emmanuelle Charpentier discovered that CRISPR—Clustered Regularly Interspaced Short Palindromic Repeats—could be programmed to

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

cut any DNA sequence with extraordinary precision . Eight years later, they received the Nobel Prize in Chemistry for this breakthrough .

The story begins in the archives of bacterial evolution. Eugene Koonin, an NIH distinguished investigator, first recognized in 2005 that "spacer DNA" in bacterial CRISPR regions matched sequences of bacteriophages, suggesting an adaptive immune function . Bacteria had been using this system for millions of years to remember and destroy viral invaders. Doudna and Charpentier realized they could harness this molecular scissors system for any genetic target.

The elegance of CRISPR-Cas9 lies in its simplicity. The system requires only two components: the Cas9 protein, a programmable nuclease, and a single guide RNA (sgRNA) that directs Cas9 to the target DNA site . Once introduced into cells, CRISPR induces double-strand breaks at specified genomic locations, activating DNA repair mechanisms that can generate insertions, deletions, or precise corrections .



Figure 1: The CRISPR-Cas9 complex showing the Cas9 protein (gold), guide RNA (red), and target DNA (blue) at the cleavage site. Image: Science Photo Library.

This discovery democratized gene editing. Unlike previous technologies—Zinc Finger Nucleases (ZFNs) discovered in 1995 and TALENs developed in 2011—CRISPR was faster, cheaper, and accessible to virtually any laboratory . The technology exploded across research domains, from chromatin imaging to preclinical disease modeling .

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

From Laboratory to Clinic—The First CRISPR Cures

The transition from laboratory curiosity to clinical reality accelerated dramatically in 2023. On December 8, 2023, the FDA approved Casgevy (exagamglogene autotemcel), the first CRISPR-based gene therapy, for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TBT) in patients aged 12 and older .

Casgevy represents a paradigm shift in treating genetic blood disorders. The therapy works by editing hematopoietic stem and progenitor cells (HSPCs) ex vivo. Researchers target the erythroid-specific enhancer region of the BCL11A gene, which normally suppresses fetal hemoglobin production in adults . By disrupting this regulatory element, Casgevy reactivates fetal hemoglobin (HbF) synthesis, compensating for defective adult hemoglobin in SCD patients.

Clinical trials demonstrated transformative results. Patients receiving Casgevy showed significantly elevated HbF levels and dramatic reductions in vaso-occlusive crises—the painful, life-threatening complications of sickle cell disease . Unlike conventional treatments requiring lifelong transfusions or bone marrow transplants from matched donors, Casgevy offers a one-time, potentially curative intervention.



Figure 2: The basic process of gene therapy showing cell collection, genetic modification, and reinfusion. Image: Dana-Farber/Boston Children's.

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

The approval triggered rapid commercial rollout. Within 18 months, 50 active treatment sites opened across North America, the European Union, and the Middle East . However, challenges emerged immediately. Each treatment costs approximately $2.2-3.1 million per patient, raising profound questions about healthcare equity and insurance coverage . Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy's developers, have negotiated reimbursement agreements with Medicaid programs and the UK's National Health Service based on treatment effectiveness .

The New Frontier—In Vivo Editing and Personalized Medicine

While Casgevy requires ex vivo cell modification, 2024 and 2025 witnessed breakthroughs in in vivo (direct body) gene editing. In a remarkable medical milestone, the first personalized CRISPR therapy was administered to an infant named KJ in late 2024 . Born with carbamoyl phosphate synthetase 1 (CPS1) deficiency—a rare urea cycle disorder that is typically fatal in newborns—KJ received a bespoke CRISPR treatment developed and delivered in just six months .

This landmark case, led by researchers at the Innovative Genomics Institute and Children's Hospital of Philadelphia, demonstrated that custom gene therapies could be created for individual patients with ultra-rare genetic diseases . The therapy targeted the Q335X mutation in KJ's CPS1 gene, successfully editing 42% of liver cells in preclinical models .

The FDA recognized this achievement by unveiling the "plausible mechanism" framework in February 2026—a new regulatory pathway for personalized genetic medicines . This approach allows data from a few patients to support broader approvals when targeting specific genetic abnormalities, potentially eliminating the need for 100 separate clinical trials for 100 distinct mutations in the same gene .

Figure 3: A scientist performs precision pipetting for gene editing research. Image: PBS NewsHour/Getty Images.

Intellia Therapeutics advanced another in vivo approach with NTLA-2002 for hereditary angioedema (HAE), a condition causing recurrent, life-

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

threatening swelling attacks . Delivered via lipid nanoparticles, this therapy targets the KLKB1 gene, achieving over 90% reduction in inflammatory protein levels in early trials . The company launched a global Phase 3 trial in 2024 to confirm these results across diverse populations .

Cardiovascular disease represents another promising frontier. Verve Therapeutics' Verve-101 uses base editing—a refined CRISPR variant that changes single DNA letters without double-strand breaks—to modify the PCSK9 gene in the liver, reducing cholesterol levels beyond what traditional statins achieve . Early results showed significant LDL cholesterol reduction, though the FDA required additional safety data following cardiovascular events in some participants .

Beyond CRISPR—Base Editing and Epigenetic Modification

First-generation CRISPR-Cas9 creates double-strand DNA breaks, which can trigger unwanted cellular responses or chromosomal rearrangements. Next-generation technologies address these limitations through precision refinement.

Base editing, pioneered by David Liu at the Broad Institute, chemically changes one DNA base to another without cutting both DNA strands . This "molecular pencil" can correct point mutations—the cause of many genetic diseases—while minimizing off-target effects and cellular stress responses.

At the National Institutes of Health, researchers led by Suk See De Ravin applied base editing to treat inborn errors of immunity (IEIs). Using CRISPR-Cas9 base editors, they corrected single-base mutations in chronic granulomatous disease without disrupting other genomic regions . The approach achieved over 60% genetic correction with significantly improved immune cell function, supporting FDA approval for first-in-human trials .

Epigenetic editing represents another evolutionary leap. Chroma Medicine (now nChroma Bio after merging with Nvelop Therapeutics in December 2024) developed technology that modifies gene expression without changing the underlying DNA sequence . By adding or removing methylation marks—chemical tags that control gene activity—this approach can silence or activate genes reversibly, avoiding permanent genomic alterations .

In preclinical experiments, Chroma demonstrated simultaneous epigenetic modulation of three genes in human T cells, achieving durable silencing without detectable insertions, deletions, or chromosomal rearrangements . Their lead program, CRMA-1001, targets hepatitis B and D through liver-directed epigenetic therapy .

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

The Safety Landscape—Managing Off-Target Effects

Despite remarkable precision, gene editing carries risks. Off-target effects—unintended DNA modifications at sites similar to the target sequence—remain the primary safety concern. Early CRISPR systems produced off-target edits at frequencies ranging from 0.1% to several percent, depending on guide RNA design and cellular context .

Advanced computational prediction and protein engineering have dramatically improved specificity. The CRISOT-Opti system uses RNA-DNA interaction fingerprints to predict and optimize guide RNAs, reducing off-target reads by approximately 50-fold—from 51,967 to 1,072 in validation studies . Engineered Cas9 variants like evoCas9, developed through high-throughput yeast screening, reduce off-target sites by 98.7% while maintaining robust on-target activity .

Paired nickase strategies—using two modified Cas9 enzymes that each cut only one DNA strand—further enhance specificity by requiring simultaneous targeting of both strands . This approach reduces off-target effects markedly, though identifying properly positioned guide RNA pairs remains challenging given PAM sequence constraints .

Long-term safety monitoring is essential. Because gene editing creates permanent genomic changes, the FDA requires sponsors to establish patient registries for extended follow-up, capturing rare adverse events or delayed complications that may emerge years after treatment . For approved therapies like Casgevy, post-market surveillance will track patients for 15 years to assess durability and safety .

Ethical Frameworks and Regulatory Evolution

The power to rewrite genetic code demands robust ethical oversight. The 2018 case of He Jiankui—who created the world's first gene-edited babies in China—triggered global condemnation and accelerated regulatory responses . The Third International Summit on Human Genome Editing reaffirmed in 2023 that human germline editing (heritable genetic changes) remains unacceptable until safety, ethical, and governance standards are established .

China responded with strengthened oversight. In July 2024, the Medical Ethics Subcommittee of China's Ministry of Science and Technology banned all clinical research involving germline editing . New Measures for the Ethical Review of Life Science and Medical Research Involving Humans expanded ethical review to include human cells, tissues, organs, embryos, and fetuses, requiring enhanced informed consent for clinical studies .

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

In the United States, germline editing research is prohibited with federal funds, though private research continues under FDA and institutional oversight . The FDA's Center for Biologics Evaluation and Research (CBER) maintains rigorous standards for gene therapy approval, requiring substantial evidence of safety and efficacy through preclinical testing, carefully designed clinical trials, and robust manufacturing controls .

The regulatory landscape continues evolving. The FDA's "plausible mechanism" framework represents a revolutionary advance in regulatory science, potentially accelerating approvals for ultra-rare diseases while maintaining safety standards . As FDA Commissioner Marty Makary and CBER Director Vinay Prasad noted, this pathway recognizes that "when biology is clear and the science is sound, we will evaluate therapies based upon strong evidence and not arbitrary barriers" .

Market Dynamics and Global Impact

The gene editing market is experiencing explosive growth. Valued at approximately $9.75-11.29 billion in 2024-2025, the market is projected to reach $42-47 billion by 2034-2035, expanding at compound annual growth rates of 15-16% . North America dominates with 49-53% market share, driven by advanced healthcare infrastructure, substantial R&D investment, and supportive regulatory frameworks .

CRISPR technology commands the largest technology segment, holding approximately 75% market share in 2025 . Applications span therapeutic development (particularly for rare genetic diseases and oncology), agricultural improvement, and research tools. The reagents and consumables segment leads product categories, accounting for nearly 60% of revenue .

Pharmaceutical and biotechnology companies represent the primary end-users, comprising over 50% of the market . Major players including Thermo Fisher Scientific, Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics drive innovation through strategic partnerships and substantial R&D investment .

Agricultural applications are expanding rapidly. China announced in February 2024 that gene-edited wheat, corn, soybeans, and rapeseed varieties developed between 2024-2028 would advance through expedited regulatory pathways, aiming to enhance food security through improved crop yields and disease resistance . These applications avoid the transgenic foreign DNA insertion that characterizes traditional GMOs, potentially facing lower regulatory barriers and greater public acceptance.

The Road Ahead—Challenges and Opportunities

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

As gene editing matures from experimental tool to clinical reality, several critical challenges demand attention. Cost and accessibility remain paramount. With treatments priced at millions of dollars per patient, ensuring equitable access across socioeconomic and geographic boundaries requires innovative reimbursement models, potentially including outcome-based pricing where payment is contingent on therapeutic success .

Technical limitations persist. While CRISPR excels at disrupting genes or making small corrections, inserting large DNA segments or correcting complex chromosomal rearrangements remains difficult. Delivery challenges—getting editing machinery to the right cells in vivo without immune responses—continue limiting applications for neurological and muscular diseases .

The ethical discourse must evolve alongside technology. As editing precision improves and costs decline, pressure will mount to expand applications beyond serious diseases to enhancement purposes—improving intelligence, athletic performance, or cosmetic traits. Societies must establish democratic deliberation processes to define acceptable boundaries, balancing individual autonomy against concerns about genetic inequality and the commodification of human capabilities.

Despite these challenges, the trajectory is clear. From the first bacterial spacer sequences recognized by Eugene Koonin in 2005, through Doudna and Charpentier's molecular insights in 2012, to the FDA approval of Casgevy in 2023 and personalized therapies for infants in 2024-2025, gene editing has demonstrated remarkable capacity to alleviate human suffering .

The next decade will likely witness approvals for CRISPR therapies targeting common diseases including cardiovascular conditions, cancer immunotherapies, and infectious diseases. The convergence of artificial intelligence for target identification, improved delivery vehicles, and refined editing enzymes promises to accelerate this transformation .

We stand at an inflection point in human history—the moment when our species gained the ability to read and write its own genetic code. How we wield this power will define not just the future of medicine, but the future of humanity itself.

References

1. Akilimali A, Singh A, et al. (2024). FDA approves CASGEVY, the first CRISPR/Cas9 gene editing therapy for sickle cell disease. PMC, 11305803. https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/

ISSN: 3060-4737 Volume 3, Issue 4 IF(Impact Factor) 10.98 / 2025

2. Gene Editing: Developments, Ethical Considerations, and Future Directions (2023). PMC, 11759082. https://pmc.ncbi.nlm.nih.gov/articles/PMC11759082/

3. The impact of the three major human genome editing reports on the governance landscape (2018). PMC, 12401782. https://pmc.ncbi.nlm.nih.gov/articles/PMC12401782/

4. FDA illuminates new approval pathway for bespoke gene editing therapies (2026). Fierce Biotech.

https://www.fiercebiotech.com/biotech/fda-illuminates-new-approval-pathway-bespoke-gene-therapies

5. What's Cooking With CRISPR? (2025). NIH Catalyst, 33(1). https://irp.nih.gov/system/files/media/file/2025-01/v33i1_nih-catalyst_jan-feb-2025_24pages_web.pdf

6. Ten CRISPR companies to watch in 2025 (2025). Lab iotech. https://www.labiotech.eu/best-biotech/crispr-companies/

7. How many FDA approved Gene editing are there? (2025). Synapse Patsnap. https://synapse.patsnap.com/article/how-many-fda-approved-gene-editing-are-there

8. FDA-Approved Gene Therapies (2024). Boston Children's Hospital. https://www.childrenshospital.org/services/gene-therapy-program/fda-approved-gene-therapies

9. Future of CRISPR: Tech Heralds Landmark Clinical Trials (2024). The Cardiology Advisor. https://www.thecardiologyadvisor.com/features/future-of-crispr/

10. CRISPR Clinical Trials: A 2025 Update (2025). Innovative Genomics Institute. https://innovativegenomics.org/news/crispr-clinical-trials-2025/

11. CRISPR Clinical Trials to Follow (2025). Synthego. https://www.synthego.com/blog/crispr-clinical-trials/